Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity

Xenotransplantation

Volumn 11, Issue 1, 2004, Pages 43-52

  Matter Reissmann, Ulrike B ^a   Sonntag, Kai Christian ^b   Gilli, Urs O ^a   Leguern, Christian ^c   Schneider, Mårten K J ^a   Seebach, Jörg D ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MCLEAN HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adhesion; Cytotoxicity; Endothelial cells; Fas; Fas ligand; NK cells; Xenotransplantation

Indexed keywords

FAS LIGAND;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SHEAR STRESS; SPECIES DIFFERENCE; SWINE; TRANSCYTOSIS; VASCULARIZATION; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL ADHESION; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIAL CELLS; FAS LIGAND PROTEIN; HUMANS; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; NEUTROPHIL INFILTRATION; NEUTROPHILS; SOLUBILITY; SWINE; T-LYMPHOCYTES; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0742323550     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2004.00081.x     Document Type: Article

References (54)

1. COOPER DK, GOLLACKNER B, SACHS DH. Will the pig solve the transplantation backlog? Annu Rev Med 2002; 53: 133.
2. TAUB DD, ANVER M, OPPENHEIM JJ, LONGO DL, MURPHY WJ. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996; 97: 1931.
3. ROBINSON LA, TU L, STEEBER DA, PREIS O, PLATT JL, TEDDER TF. The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium: implications for xenotransplantation. J Immunol 1998; 161: 6931.
4. SCHNEIDER MK, FORTE P, SEEBACH JD. Adhesive interactions between human NK cells and porcine endothelial cells. Scand J Immunol 2001; 54: 70.
5. SEEBACH JD, WANECK GL. Natural killer cells in xenotransplantation. Xenotransplantation 1997; 4: 201.
6. BROUARD S, GAGNE K, Blancho G, Soulillou JP. T cell response in xenorecognition and xenografts: a review. Hum Immunol 1999; 60: 455.
7. ITOH N, YONEHARA S, ISHII A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233.
8. SHARMA K, WANG RX, ZHANG LY et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88: 333.
9. SUDA T, OKAZAKI T, NAITO Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806.
10. ARASE H, ARASE N, SAITO T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181: 1235.
11. GREEN DR, FERGUSON TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001; 2: 917.
12. WANG T, DONG C, STEVENSON SC et al. Overexpression of soluble fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation 2002; 106: 1536.
13. BELLGRAU D, GOLD D, SELAWRY H et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
14. LAU HT, YU M, FONTANA A, STOECKERT Jr CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
15. ARAI H, CHAN SY, BISHOP DK, NABEL GJ. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997; 3: 843.
16. SWENSON KM, KE B, WANG T et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998; 65: 155.
17. LI XK, OKUYAMA T, TAMURA A et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998; 66: 1416.
18. GEORGANTAS RW III, LEONG KW, AUGUST JT. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum Gene Ther 2000; 11: 851.
19. MATSUE H, MATSUE K, WALTERS M et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999; 5: 930.
20. MIN WP, GORCZYNSKI R, HUANG XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164: 161.
21. CHERVONSKY AV, WANG Y, WONG FS et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17.
22. ALLISON J, GEORGIOU HM, STRASSER A, VAUX DL. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
23. KANG SM, SCHNEIDER DB, LIN ZH et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
24. MURUVE DA, NICOLSON AG, MANFRO RC et al. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997; 8: 955.
25. TAKEUCHI T, UEKI T, NISHIMATSU H et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999; 162: 518.
26. TURVEY SE, GONZALEZ-NICOLINI V, KINGSLEY CI et al. Fas ligand-transfected myoblasts and islet cell transplantation. Transplantation 2000; 69: 1972.
27. CACALANO G, LEE J, KIKLY K et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994; 265: 682.
28. MIWA K, ASANO M, HORAI R et al. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287.
29. SEINO K, IWABUCHI K, KAYAGAKI N et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161: 4484.
30. OTTONELLO L, TORTOLINA G, AMELOTTI M, DALLEGRI F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162: 3601.
31. WAJANT H, PfiZENMAIER K, SCHEURICH P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14: 53.
32. TRAN TH, GREY S, ANRATHER J et al. Regulated and endothelial cell-specific expression of Fas ligand: an in vitro model for a strategy aiming at inhibiting xenograft rejection. Transplantation 1998; 66: 1126.
33. YI S, FENG X, WANG Y et al. CD4+ cells play a major role in xenogeneic human anti-pig cytotoxicity through the Fas/Fas ligand lytic pathway. Transplantation 1999; 67: 435.
34. DULAT HJ, Von GRUMBKOW C, BAARS W et al. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol 2001; 31: 2217.
35. RODRIGUEZ-GAGO M, De HEREDIA A, RAMIREZ P et al. Human anti-porcine gammadelta T-cell xenoreactivity is inhibited by human FasL expression on porcine endothelial cells. Transplantation 2001; 72: 503.
36. TSUYUKI S, KONO M, BLOOM ET. Cloning and potential utility of porcine Fas ligand: overexpression in porcine endothelial cells protects them from attack by human cytolytic cells. Xenotransplantation 2002; 9: 410.
37. SEEBACH JD, SCHNEIDER MK, COMRACK CA et al. Immortalized bone-marrow derived pig endothelial cells. Xenotransplantation 2001; 8: 48.
38. YAGITA H, SEINO K, KAYAGAKI N, OKUMURA K. CD95 ligand in graft rejection. Nature 1996; 379: 682.
39. O'CONNELL J, O'SULLIVAN GC, COLLINS JK, SHANAHAN F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075.
40. SEEBACH JD, YAMADA K, MCMORROW I, SACHS DH, DERSIMONIAN H. Xenogeneic human anti-pig cytotoxicity mediated by activated natural killer cells, Xenotransplantation 1996; 3: 188.
41. SEEBACH JD, BARTHOLDI D, FREI K et al. Experimental Listeria meningoencephalitis: macrophage inflammatory protein (MIP)-1α and -2 are produced intrathecally and mediate chemotactic activity in cerebrospinal fluid of infected mice. J Immunol 1995; 155: 4367.
42. SEEBACH JD, COMRACK C, GERMANA S et al. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655.
43. STAMPER HB, WOODRUFF JJ. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. J Exp Med 1976; 144: 828.
44. SCHNEIDER MK, STRASSER M, GILLI UO et al. Rolling adhesion of human NK cells to porcine endothelial cells mainly relies on CD49d-CD106 interactions. Transplantation 2002; 73: 789.
45. SATA M, WALSH K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4: 415.
46. ARAI H, GORDON D, NABEL EG, NABEL GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862.
47. RICHARDSON BC, LALWANI ND, JOHNSON KJ, MARKS RM. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994; 24: 2640.
48. MATTER-REISSMANN UB, FORTE P, SCHNEIDER MK et al. Xenogeneic human NK cytotoxicity against porcine endothelial cells is perforin/granzyme B dependent and not inhibited by Bcl-2 overexpression. Xenotransplantation 2002; 9: 325.
49. SUDA T, HASHIMOTO H, TANAKA M, OCHI T, N AGATA S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045.
50. HOHLBAUM AM, MOE S, MARSHAK-ROTHSTEIN A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191: 1209,
51. TORTORELLA C, PIAZZOLLA G, SPACCAVENTO F et al. Spontaneous and Fas-induced apoptotic cell death in aged neutrophils. J Clin Immunol 1998; 18: 321.
52. SATA M, LUO Z, WALSH K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 2001; 166: 6964.
53. SATA M, WALSH K. Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels. J Mol Cell Cardiol 2000; 32: 1395.
54. MALYGUINE AM, SAADI S, PLATT JL, DAWSON JR. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996; 61: 161.